Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
Mease P, Helliwell P, Silwinska-Stanczyk P, Miakisz M, Ostor A, Peeva E, Vincent MS, Sun Q, Sikirica V, Winnette R, Qiu R, Li G, Feng G, Beebe JS, Martin DA.
Mease P, et al.
Arthritis Rheumatol. 2023 Aug;75(8):1370-1380. doi: 10.1002/art.42519. Epub 2023 Jun 22.
Arthritis Rheumatol. 2023.
PMID: 37194394
Free article.
Clinical Trial.